Gori Niccolò, Galluzzo Marco, Chiricozzi Andrea, Grieco Teresa, Chello Camilla, Russo Filomena, Tolino Ersilia, Pigliacelli Flavia, Mazzotta Anna Maria, Talamonti Marina, Paganini Claudia, Caldarola Giacomo, Cocuroccia Barbara, Antonelli Flaminia, Boeti Luisa, Giordano Domenico, Bianchi Luca, De Simone Clara, Pellacani Giovanni, Peris Ketty
Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Dermatology. 2025;241(3):223-229. doi: 10.1159/000545227. Epub 2025 Apr 23.
The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands, and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Upadacitinib, a selective inhibitor of the JAK1 enzyme, showed promising results in the treatment of AD located in sensitive areas in clinical trials. The aim of this multicenter observational study was to better characterize the effectiveness of upadacitinib in sensitive areas, using specific clinimetric tools.
In this multicenter observational retrospective and prospective study, we enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area, treated with upadacitinib with at least 16 weeks.
Over the course of the 52-week study period, upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas.
Our study demonstrates a significant benefit for patients with AD affecting sensitive areas when treated with upadacitinib, supporting its use first-line therapeutic choice for this specific subset of patients.
即使目前有一系列生物疗法问世，治疗累及敏感部位（头颈部、手部和生殖器）的特应性皮炎（AD）仍然是一项重大挑战。乌帕替尼是一种JAK1酶的选择性抑制剂，在临床试验中，它在治疗累及敏感部位的AD方面显示出了有前景的结果。这项多中心观察性研究的目的是使用特定的临床测量工具，更好地描述乌帕替尼在敏感部位的有效性。
在这项多中心观察性回顾性和前瞻性研究中，我们纳入了74例成年患者（41名女性和37名男性，平均年龄33.8岁），他们患有中度至重度AD，至少有一个敏感部位受累，接受乌帕替尼治疗至少16周。
在为期52周的研究期间，乌帕替尼在减轻敏感部位的AD症状及相关临床表现方面显示出显著疗效。
我们的研究表明，对于累及敏感部位的AD患者，使用乌帕替尼治疗有显著益处，支持将其作为这一特定患者亚群的一线治疗选择。
